Imagion Biosystems gave ASX information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal